Tiambeng Timothy N, Yan Yuetian, Patel Shailin K, Cotham Victoria C, Wang Shunhai, Li Ning
Analytical Chemistry, Regeneron Pharmaceuticals Inc., Tarrytown, NY 10591-6707, USA.
Analytical Chemistry, Regeneron Pharmaceuticals Inc., Tarrytown, NY 10591-6707, USA.
J Pharm Biomed Anal. 2025 Jan 15;253:116524. doi: 10.1016/j.jpba.2024.116524. Epub 2024 Oct 16.
Recombinant adeno-associated viruses (AAVs) are a highly effective platform for gene delivery for the treatment of many human diseases. Characterization of AAV viral protein attributes (VP), such as serotype identity, VP stoichiometry, and VP post-translational modifications, is essential to ensure product and process consistency. While size-exclusion chromatography (SEC) coupled with mass spectrometry (MS) is commonly used in the biopharmaceutical industry for analyzing protein therapeutics, its application to intact AAV VP components has not gained traction, presumably due to difficulties in achieving adequate resolution of VP(1-3) monomers. Herein, we describe the development of a denaturing SEC method and optimization of SEC parameters, including stationary phase pore size, column temperature, and mobile phase composition, to achieve effective chromatographic separation of VP(1-3). We demonstrate that an optimized dSEC-MS method featuring MS-compatible formic acid, can effectively separate VP(1-3) across AAV1, 2, 5, 6, 8, and 9 serotypes using a single column and mobile phase condition. A case study was included to showcase successful application of the dSEC-MS method in analyzing changes across different AAV production processes, yielding similar conclusions to an orthogonal approach, such as hydrophilic interaction chromatography (HILIC)- MS. Additionally, dSEC integrated with fluorescence (FLR) and ultraviolet (UV) detection can be used to semi-quantitatively identify both AAV DNA and VP components from empty and full AAV samples. Overall, this robust and MS-friendly methodological advancement could greatly streamline the development and analytical quality control processes for AAV-based gene therapies, providing a highly sensitive method for intact VP characterization.
重组腺相关病毒(AAV)是用于治疗多种人类疾病的基因递送的高效平台。对AAV病毒蛋白属性(VP)进行表征,如血清型鉴定、VP化学计量以及VP翻译后修饰,对于确保产品和工艺的一致性至关重要。虽然尺寸排阻色谱法(SEC)与质谱法(MS)联用在生物制药行业中常用于分析蛋白质治疗剂,但其在完整AAV VP组分分析中的应用尚未得到广泛应用,可能是由于难以实现VP(1-3)单体的充分分离。在此,我们描述了一种变性SEC方法的开发以及SEC参数的优化,包括固定相孔径、柱温和流动相组成,以实现VP(1-3)的有效色谱分离。我们证明,一种采用与MS兼容的甲酸的优化dSEC-MS方法,能够使用单一色谱柱和流动相条件,有效分离AAV1、2、5、6、8和9血清型的VP(1-3)。纳入了一个案例研究,以展示dSEC-MS方法在分析不同AAV生产工艺变化中的成功应用,得出与亲水相互作用色谱法(HILIC)-MS等正交方法相似的结论。此外,与荧光(FLR)和紫外(UV)检测相结合的dSEC可用于半定量鉴定空AAV和完整AAV样品中的AAV DNA和VP组分。总体而言,这一强大且对MS友好的方法学进展可极大地简化基于AAV的基因治疗的开发和分析质量控制流程,为完整VP表征提供一种高灵敏度方法。